Digestive Diseases and Sciences

, Volume 39, Issue 11, pp 2497–2502

Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C

Evaluation of HCV genotypes during and after long-term follow-up

Authors

  • Giulio Diodati
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Paola Bonetti
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Alessandro Tagger
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Carla Casarin
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Franco Noventa
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Marilisa Ribero
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Michele Fasola
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Arturo Ruol
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
  • Giuseppe Realdi
    • From the Istituto di Medicina ClinicaUniversity of Padova
    • Istituto di VirologiaUniversity of Milano
    • Istituto di IgieneUniversity of Milano
    • Clinica Medica GeneraleUniversity of Sassari
Liver: Infectious, Inflammatory, And Metabolic Disorders

DOI: 10.1007/BF02087672

Cite this article as:
Diodati, G., Bonetti, P., Tagger, A. et al. Digest Dis Sci (1994) 39: 2497. doi:10.1007/BF02087672

Abstract

Hepatitis C virus is the most frequent cause of chronic non-A, non-B hepatitis, and the antibodies to structural and nonstructural proteins encoded by viral genome have been suggested to be markers of ongoing HCV infection. We studied the behavior of these antibodies during interferon therapy in 18 patients with chronic hepatitis C and also during a follow-up period of at least four years. A significant decrease of anti-HCV titer was found only in patients who had shown positive response to therapy and all of them were anti-HCV negative at the end of follow-up. Analysis by recombinant immunoblotting assay showed that only anti-c100 were affected by interferon therapy, whereas anti-c22 and anti-c33 were not modified. Using polymerase chain reaction to detect small amounts of HCV genome in serum, we could confirm that the behavior of HCV-RNA during and after interferon therapy is similar to that of anti-HCV and the loss of anti-c100 seems to be closely related to HCV-RNA disappearance from serum. Our patients with chronic hepatitis C were found to be of type 1b and 2, according to the recent score of Simmonds, and the clearance of serum HCV-RNA during treatment and its sustained negative status are closely related to genotype 2 and to long-term positive response to interferon.

Key words

hepatitis C virusHCV markersinterferon therapyHCV genotypes
Download to read the full article text

Copyright information

© Plenum Publishing Corporation 1994